Thibaud Valentin
French Institute of Health and Medical Research
38 Papers
30 Citations
Thibaud Valentin is an academic researcher from French Institute of Health and Medical Research. The author has contributed to research in topics: Medicine & Sarcoma. The author has an hindex of 8, co-authored 24 publications.
Chat about Author
Papers
Management and prognosis of malignant peripheral nerve sheath tumors: The experience of the French Sarcoma Group (GSF-GETO).
Thibaud Valentin,A. Le Cesne,I.L. Ray-Coquard,Antoine Italiano,Gauthier Decanter,Emmanuelle Bompas,N. Isambert,Juliette Thariat,Claude Linassier,François Bertucci,Jacques-Olivier Bay,Audrey Bellesoeur,Nicolas Penel,S. Le Guellec,Thomas Filleron,Christine Chevreau +15 more
TL;DR: For operated patients, this series showed a worse prognosis for NF1-related MPNST, due to different clinical features at diagnosis, more than NF1 status itself, as well as correlative analyses on these patients, using the latest molecular tools.
142
Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): a randomised phase 2 trial
Axel Le Cesne,Jean-Yves Blay,Julien Domont,Emmanuelle Tresch-Bruneel,Christine Chevreau,François Bertucci,Corinne Delcambre,Esma Saada-Bouzid,Sophie Piperno-Neumann,Jacques-Olivier Bay,Olivier Mir,Isabelle Ray-Coquard,Thomas Ryckewaert,Thibaud Valentin,Nicolas Isambert,Antoine Italiano,Stéphanie Clisant,Nicolas Penel +17 more
TL;DR: In this article, the authors report the final analysis of a phase 2 trial investigating the clinical benefit of continuation of trabectedin treatment until progression versus interruption of therapy after six treatment cycles in patients with advanced soft tissue sarcoma.
89
Sorafenib in patients with progressive malignant solitary fibrous tumors: a subgroup analysis from a phase II study of the French Sarcoma Group (GSF/GETO)
Thibaud Valentin,Charles Fournier,Nicolas Penel,Emmanuelle Bompas,Loic Chaigneau,N. Isambert,Christine Chevreau +6 more
TL;DR: The data suggest a potential efficacy of sorafenib in SFT, and further investigation is needed to confirm these data.
52
Surgical Margins and Adjuvant Therapies in Malignant Phyllodes Tumors of the Breast: A Multicenter Retrospective Study
Mathias Neron,Christophe Sajous,S. Thezenas,Sophie Piperno-Neumann,Fabien Reyal,Marick Laé,Camille Chakiba,A. Michot,Nicolas Penel,Charles Honoré,Clémentine Owen,François Bertucci,Sébastien Salas,Esma Saada-Bouzid,Thibaud Valentin,Emmanuelle Bompas,Mehdi Brahmi,Isabelle Ray-Coquard,Jean-Yves Blay,Nelly Firmin +19 more
TL;DR: It is suggested that 3 mm margins are necessary and sufficient for surgical management of MPTs, and emphasizes the importance of SS to obtain clear margins in case of 0–1–2 mm margin.
44
Pembrolizumab in patients with rare and ultra-rare sarcomas (AcSé Pembrolizumab): analysis of a subgroup from a non-randomised, open-label, phase 2, basket trial.
Jean-Yves Blay,Sylvie Chevret,Axel Le Cesne,Mehdi Brahmi,Nicolas Penel,Sophie Cousin,François Bertucci,Emmanuelle Bompas,Thomas Ryckewaert,Pauline Soibinet,Pascaline Boudou-Rouquette,Patrick Soulié,Thibaud Valentin,Jean-Pierre Lotz,D. Tosi,Zoé Neviere,Mathilde Cancel,Isabelle Ray-Coquard,Laetitia Gambotti,Assia Lamrani-Ghaouti,Clotilde Simon,Caroline Even,Christophe Massard +22 more
TL;DR: The AcSé Pembrolizumab study as mentioned in this paper is an ongoing phase 2, basket, multitumour study investigating the activity of pembrolizer-based monotherapy in rare and ultra-rare sarcomas.
35